Cost-effectiveness of polymyxin B hemoperfusion for septic shock: an observational study using a Japanese nationwide administrative database

Table 5 Subgroup analyses

SOFA range	Cause of sepsis	The number of patients (n)		Hospital mortality (%)		Total cost (Euro)		Difference in cost (Euro)	Difference in life expectancy (yrs)	Difference of LYG (years)	Difference of QALY (years)	ICER (Euro/year)
SOFA range	Cause of sepsis	PMX	Control	PMX	Control	PMX	Control	Difference in cost (Euro)	Difference in life expectancy (yrs)	Difference of LYG (years)	Difference of QALY (years)	ICER (Euro/year)
7–9	Abdominal	153	274	15.7	34.3	31,734	25,782	5952	3.40	1.73	1.20	4974
7–9	Others	333	1190	24.0	28.7	28,374	21,373	7001	1.50	0.77	0.53	13,263
10–12	Abdominal	153	305	24.8	44.6	35,723	31,883	3840	2.66	1.36	0.94	4102
10–12	Others	326	1126	28.5	37.0	32,359	25,448	6911	1.58	0.81	0.56	12,429

SOFA Sequential organ failure assessment, LYG Life year gained, QALY Quality-adjusted life-year, ICER Incremental cost-effectiveness ratio

ISSN: 2731-3786